Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853423 · ClinicalTrials.gov registry record · Phase 1
Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream
A Phase 1 study, sponsored by Le Bonheur Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01853423 is a Phase 1 study that has completed, run by Le Bonheur Children's Hospital. The registered enrollment target is 11 participants.
The verdict
NCT01853423, a Phase 1 study, has completed, sponsored by Le Bonheur Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of a 0.1% formulation of rapamune cream in children with Tuberous Sclerosis Complex (TSC), ages 3 years and older, who have facial angiofibromas that would benefit from treatment.
Interventions
- DRUG Rapamune
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01853423
The ClinicalTrials.gov registry entry for NCT01853423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Le Bonheur Children's Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rapamune is the first listed.
NCT01853423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01853423 about?
NCT01853423 is a clinical study titled "Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream". The objective of this study is to evaluate the safety and efficacy of a 0.1% formulation of rapamune cream in children with Tuberous Sclerosis Complex (TSC), ages 3 years and older, who have facial angiofibromas that would benefit from treatment.
What is the current status of trial NCT01853423?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-10. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01853423?
The interventions under investigation include: Rapamune (DRUG).
Who is sponsoring clinical trial NCT01853423?
This trial is sponsored by Le Bonheur Children's Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.